相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Physical Chemistry of Nanomedicine: Understanding the Complex Behaviors of Nanoparticles in Vivo
Lucas A. Lane et al.
ANNUAL REVIEW OF PHYSICAL CHEMISTRY, VOL 66 (2015)
Analysis of human innate immune responses to PRINT fabricated nanoparticles with cross validation using a humanized mouse model
Gregory R. Robbins et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2015)
Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer
Rodrigo Dienstmann et al.
CANCER DISCOVERY (2015)
Beyond BRAF: where next for melanoma therapy?
I. V. Fedorenko et al.
BRITISH JOURNAL OF CANCER (2015)
MicroRNA silencing for cancer therapy targeted to the tumour microenvironment
Christopher J. Cheng et al.
NATURE (2015)
Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates
Trinna L. Cuellar et al.
NUCLEIC ACIDS RESEARCH (2015)
Investigating the Impact of Nanoparticle Size on Active and Passive Tumor Targeting Efficiency
Edward A. Sykes et al.
ACS NANO (2014)
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
Nicolas Bertrand et al.
ADVANCED DRUG DELIVERY REVIEWS (2014)
Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis
Sonia A. Melo et al.
CANCER CELL (2014)
A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors
Anthony W. Tolcher et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology
Ligia Catarina Gomes-da-Silva et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2014)
First-in-Human Phase I Study of the Liposomal RNA Interference Therapeutic Atu027 in Patients With Advanced Solid Tumors
Beate Schultheis et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Development of a liver-targeted siRNA delivery platform with a broad therapeutic window utilizing biodegradable polypeptide-based polymer conjugates
Stephanie E. Barrett et al.
JOURNAL OF CONTROLLED RELEASE (2014)
Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing
Jayaprakash K. Nair et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2014)
Systemic Delivery of a miR34a Mimic as a Potential Therapeutic for Liver Cancer
Christopher L. Daige et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
Kevin Fitzgerald et al.
LANCET (2014)
Heterogeneity in nanoparticles influences biodistribution and targeting
Isaac M. Adjei et al.
NANOMEDICINE (2014)
Time to deliver
[Anonymous]
NATURE BIOTECHNOLOGY (2014)
Long-Distance Communication between Laryngeal Carcinoma Cells
Ieva Antanaviciute et al.
PLOS ONE (2014)
Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA
Jonathan E. Zuckerman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Investigating the optimal size of anticancer nanomedicine
Li Tang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
The role of RNA structure at 5′ untranslated region in microRNA-mediated gene regulation
Wanjun Gu et al.
RNA (2014)
The new frontier of genome engineering with CRISPR-Cas9
Jennifer A. Doudna et al.
SCIENCE (2014)
RNAi Therapies: Drugging the Undruggable
Sherry Y. Wu et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Antisense therapeutics in oncology: current status
Ammad Ahmad Farooqi et al.
ONCOTARGETS AND THERAPY (2014)
Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity
Kathryn A. Whitehead et al.
NATURE COMMUNICATIONS (2014)
Development of siRNA Payloads to Target KRAS-Mutant Cancer
Tina L. Yuan et al.
CANCER DISCOVERY (2014)
Toxicity profiling of several common RNAi-based nanomedicines: a comparative study
Dalit Landesman-Milo et al.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2014)
Imaging exosome transfer from breast cancer cells to stroma at metastatic sites in orthotopic nude-mouse models
Atsushi Suetsugu et al.
ADVANCED DRUG DELIVERY REVIEWS (2013)
Cancer nanomedicines: So many papers and so few drugs!
Vincent J. Venditto et al.
ADVANCED DRUG DELIVERY REVIEWS (2013)
In vivo disassembly of IV administered siRNA matrix nanoparticles at the renal filtration barrier
Broes Naeye et al.
BIOMATERIALS (2013)
Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology
Uma Prabhakar et al.
CANCER RESEARCH (2013)
Vesicle Trafficking and RNA Transfer Add Complexity and Connectivity to Cell-Cell Communication
Charles T. Roberts et al.
CANCER RESEARCH (2013)
Intercellular Communication by Exosome-Derived microRNAs in Cancer
Bethany N. Hannafon et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies
Glen J. Weiss et al.
INVESTIGATIONAL NEW DRUGS (2013)
Assessing the Heterogeneity Level in Lipid Nanoparticles for siRNA Delivery: Size-Based Separation, Compositional Heterogeneity, and Impact on Bioperformance
Jingtao Zhang et al.
MOLECULAR PHARMACEUTICS (2013)
Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors
Neil Senzer et al.
MOLECULAR THERAPY (2013)
Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics
Martin A. Maier et al.
MOLECULAR THERAPY (2013)
Delivery materials for siRNA therapeutics
Rosemary Kanasty et al.
NATURE MATERIALS (2013)
Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis
Teresa Coelho et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Prognostic Significance of Deregulated Dicer Expression in Breast Cancer
Emer Caffrey et al.
PLOS ONE (2013)
Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle
Scott Eliasof et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement
Josep Tabernero et al.
CANCER DISCOVERY (2013)
Safety profile of RNAi nanomedicines
Scott A. Barros et al.
ADVANCED DRUG DELIVERY REVIEWS (2012)
RNA-Based Therapeutics: Current Progress and Future Prospects
John C. Burnett et al.
CHEMISTRY & BIOLOGY (2012)
Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research
Susana Patricia Egusquiaguirre et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2012)
Tumor vasculature is a key determinant for the efficiency of nanoparticle-mediated siRNA delivery
L. Li et al.
GENE THERAPY (2012)
Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors
Dirk Strumberg et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2012)
Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs
Gina Song et al.
JOURNAL OF LIPOSOME RESEARCH (2012)
Nanoparticle Hydrophobicity Dictates Immune Response
Daniel F. Moyano et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2012)
Atelocollagen-mediated Systemic Delivery Prevents Immunostimulatory Adverse Effects of siRNA in Mammals
Shinichiro Inaba et al.
MOLECULAR THERAPY (2012)
Progress Toward In Vivo Use of siRNAs-II
Garrett R. Rettig et al.
MOLECULAR THERAPY (2012)
Fighting cancer with nanoparticle medicines-The nanoscale matters
Mark E. Davis
MRS BULLETIN (2012)
Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane
Jonathan E. Zuckerman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Multifunctional Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging Capabilities
Zhiliang Cheng et al.
SCIENCE (2012)
Therapeutic Oligonucleotides: The Road Not Taken
Cy A. Stein et al.
CLINICAL CANCER RESEARCH (2011)
Potential clinical applications of siRNA technique: benefits and limitations
Shao-Hua Chen et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2011)
siRNA Knockdown of Ribonucleotide Reductase Inhibits Melanoma Cell Line Proliferation Alone or Synergistically with Temozolomide
Jonathan E. Zuckerman et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
H. Cabral et al.
NATURE NANOTECHNOLOGY (2011)
RNA interference in the clinic: challenges and future directions
Chad V. Pecot et al.
NATURE REVIEWS CANCER (2011)
The Dicey Role of Dicer: Implications for RNAi Therapy
William M. Merritt et al.
CANCER RESEARCH (2010)
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Mark E. Davis et al.
NATURE (2010)
Strategies in the design of nanoparticles for therapeutic applications
Robby A. Petros et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice
Adam D. Judge et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
siRNA Targeted to p53 Attenuates Ischemic and Cisplatin-Induced Acute Kidney Injury
Bruce A. Molitoris et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
The First Targeted Delivery of siRNA in Humans via a Self-Assembling, Cyclodextrin Polymer-Based Nanoparticle: From Concept to Clinic
Mark E. Davis
MOLECULAR PHARMACEUTICS (2009)
Knocking down barriers: advances in siRNA delivery
Kathryn A. Whitehead et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles
Derek W. Bartlett et al.
BIOTECHNOLOGY AND BIOENGINEERING (2008)
Challenges and Opportunities for Local and Systemic Delivery of siRNA and Antisense Oligonucleotides
L. Sepp-Lorenzino et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Nanoparticle therapeutics: an emerging treatment modality for cancer
Mark E. Davis et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Dicer, Drosha, and Outcomes in Patients with Ovarian Cancer
William M. Merritt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Chemical Modification of siRNAs for In Vivo Use
Mark A. Behlke
OLIGONUCLEOTIDES (2008)
Stability Study of Unmodified siRNA and Relevance to Clinical Use
Robyn P. Hickerson et al.
OLIGONUCLEOTIDES (2008)
Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging
Derek W. Bartlett et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing
Derek W. Bartlett et al.
BIOTECHNOLOGY AND BIOENGINEERING (2007)
Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia
M. Koldehoff et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2007)
Interfering with disease: a progress report on siRNA-based therapeutics
Antonin de Fougerolles et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA
Jeremy D. Heidel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo
Jeremy D. Heidel et al.
CLINICAL CANCER RESEARCH (2007)
Gene silencing by double-stranded RNA (Nobel lecture)
Andrew Z. Fire
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2007)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Dirk Grimm et al.
NATURE (2006)
Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts:: A central role for 2′-hydroxyl uridines in immune responses
Mouldy Sioud
EUROPEAN JOURNAL OF IMMUNOLOGY (2006)
Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging
DW Bartlett et al.
NUCLEIC ACIDS RESEARCH (2006)
Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma
S Hu-Lieskovan et al.
CANCER RESEARCH (2005)
分享论文
